Good to hear your friend is getting relief. IMO these types of solutions won’t be required if the IHL trials continue to demonstrate efficacy.
IHL-42X is treating the underlying condition not just providing a mechanical intervention to improve the airway and/or ventilation. The mouth guard and CPAP are effective but crude and cumbersome. The only reason they’re tolerated is because there’s no other solution… yet.
There’s a legitimate pharmacotherapy interaction occurring based on what IHL have demonstrated so far. The full trial report with dosing has the potential to blow the absolute lid off this stock. It will be IP protected, the first and only pharmaceutical to treat OSA and a massive takeover target from big Pharma IMO.
Look at GSK moving into the cannabinol space. Long term shareholders understand the opportunity. Short term traders can look for cents in the dollar but they’ll miss all the upside we’re about to enjoy.
I no longer care what punters do because the “writing is on the wall” and IMO this stock could easily be multiple dollars.